Key result
Trial evaluates transcatheter ductal artery stenting versus surgical shunt in neonates with duct-dependent pulmonary blood flow.
Why the study?
Does transcatheter ductal artery stenting (DAS) improve important clinical outcomes over the first year of life compared to surgical systemic-to-pulmonary shunt (SPS) in neonates with congenital heart disease and ductal-dependent pulmonary blood flow?
RCT (n=236)
Randomized
Yes
Does transcatheter ductal artery stenting (DAS) improve important clinical outcomes over the first year of life compared to surgical systemic-to-pulmonary shunt (SPS) in neonates with congenital heart disease and ductal-dependent pulmonary blood flow?
This paper outlines the rationale and design of the COMPASS trial, a multicenter randomized controlled trial comparing transcatheter ductal artery stenting to surgical systemic-to-pulmonary shunt in 236 neonates with ductal-dependent pulmonary blood flow over the first year of life.
Answers are grounded in this paper and cite their sources.
COMPASS RCT will provide the first randomized evidence comparing DAS to SPS in neonates with DD-PBF; results may guide initial palliation choice.
Neonates with congenital heart disease (CHD) and ductal-dependent pulmonary blood flow (DD-PBF) require early intervention. Historically, this intervention was most often a surgical systemic-to-pulmonary shunt (SPS; e.g., Blalock-Thomas-Taussig shunt). However, over the past two decades an alternative to SPS has emerged in the form of transcatheter ductal artery stenting (DAS). While many reports have indicated safety and durability of the DAS approach, few studies compare outcomes between DAS and SPS. The reports that do exist are comprised primarily of small-cohort single-center reviews. Two multicenter retrospective studies suggest that DAS is associated with similar or superior survival compared to SPS. These studies offer the best evidence to-date, and yet both have important limitations. The authors describe herein the rationale and design of the COMPASS (COmparison of Methods for Pulmonary blood flow Augmentation: Shunt vs. Stent) Trial (NCT05268094, IDE G210212). The COMPASS Trial aims to randomize 236 neonates with DD-PBF to either DAS or SPS across approximately 27 pediatric centers in North America. The goal of this trial is to compare important clinical outcomes between DAS and SPS over the first year of life in a cohort of neonates balanced by randomization to assess whether one method of palliation demonstrates therapeutic superiority.
No takes yet. Share an insight, caveat, or question.
Petit et al. (2024) conducted an RCT in Congenital heart disease with ductal-dependent pulmonary blood flow (n=236). Transcatheter ductal artery stenting (DAS) vs. Surgical systemic-to-pulmonary shunt (SPS) was evaluated on Important clinical outcomes over the first year of life. Transcatheter ductal artery stenting versus surgical systemic-to-pulmonary shunt is being evaluated for therapeutic superiority in 236 neonates with DD-PBF over the first year of life (NCT05268094).
Synapse has enriched 10 related papers. Consider them for comparative context: